CEBPA and acute myeloid leukemia: Conversely, cytogenetic abnormalities, as well as mutations in FLT3-ITD, CEBPA, NPM1, ZRSR2, and FLT3, were predicted to have a strong positive effect on blast percentages, suggesting their roles as major drivers of AML progression.